UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **July 13, 2026**

IGC PHARMA, INC.
(Exact name of registrant as specified in charter)

Maryland	**001-32830**	**20-2760393**
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

10224 Falls Road, Potomac, Maryland 20854
(Address of principal executive offices) (Zip Code)

(301) 983-0998
(Registrant's telephone number, including area code)

Not applicable
(Former Name or Former Address, if Changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, $0.0001 par value	IGC	NYSE American

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On July 13, 2026, IGC Pharma, Inc. ("IGC" or the "Company") furnished an updated investor presentation (the "Investor Presentation"). A copy of the Investor Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company expects to use the Investor Presentation, in whole or in part and with modifications or supplements from time to time, in meetings and communications with investors, analysts, potential strategic partners and others, and at conferences and other business events.

The information contained in the Investor Presentation is summary information and should be considered in the context of the Company's filings with the Securities and Exchange Commission and its other public disclosures. The Investor Presentation speaks only as of the date of this Current Report on Form 8-K, and the Company undertakes no obligation to update or revise the Investor Presentation except as required by applicable law.

The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. By furnishing the information contained in the Investor Presentation, the Company makes no admission as to the materiality of any information therein that is required to be disclosed solely by reason of Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	IGC Pharma Investor Presentation, dated July 2026.
104	Cover Page Interactive Data File, formatted in Inline XBRL

Forward-Looking Statements:

This Current Report on Form 8-K and the Investor Presentation furnished as Exhibit 99.1 contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially, including risks related to the Company's ability to complete enrollment in its Phase 2 CALMA trial within anticipated timeframes, demonstrate safety and efficacy, obtain regulatory approvals, successfully develop and commercialize its product candidates, and achieve market acceptance, as well as other factors discussed in the Company's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-KT and subsequent reports filed with the SEC.

Forward-looking statements include, without limitation, statements regarding the anticipated timing, enrollment, conduct and results of the CALMA Phase 2 trial of IGC-AD1; the potential safety or efficacy of IGC-AD1; interim, blinded or preliminary clinical observations and the extent to which they may or may not be predictive of final results; comparisons to other products, product candidates or companies; the potential size of any addressable market; and the possibility that favorable Phase 2 results or other clinical, regulatory or business developments could result in an increase or inflection in the Company's valuation.

Any valuation metrics, valuation ranges, comparable-company analyses or potential valuation-inflection scenarios contained in the Investor Presentation are illustrative and hypothetical, are based on assumptions and circumstances that may not occur, and do not constitute an appraisal or estimate of the fair or intrinsic value of the Company or its securities, a projection or forecast of future financial performance, a price target, investment advice or a recommendation to purchase or sell any security. Comparable companies may differ materially from the Company in their stage of development, clinical results, product profiles, financial resources, market opportunities and other respects. There can be no assurance that the CALMA trial will produce favorable results or that, even if favorable results are obtained, the Company's stock price or market capitalization will increase or achieve any valuation referenced or implied in the Investor Presentation.

Interim and blinded clinical data are preliminary, are not statistically powered to demonstrate efficacy, may change as additional data become available, and are not necessarily predictive of topline or final results. IGC-AD1 is an investigational product candidate and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority. Cross-trial comparisons are not based on head-to-head clinical trials and are inherently limited.

Forward-looking statements speak only as of the date on which they are made. The Company undertakes no obligation to update or revise any forward-looking statement except as required by applicable law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

IGC Pharma, Inc.

Dated: July 13, 2026

By: /s/ Ram Mukunda
Name: Ram Mukunda
Title: Chief Executive Officer


IGCPHARMA
IGCPHARMA
Advancing Alzheimer's Care. Improving Lives.
NYSE American: IGC

SAFE HARBOR: Forward-Looking Statements and Important Cautionary Information:

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the timing, conduct and results of the CALMA Phase 2 trial; the safety and efficacy of IGC-AD1; regulatory and commercialization plans; market opportunities; and the possibility that favorable clinical results or other developments could result in an increase or inflection in IGC Pharma's valuation.

Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. These risks include the possibility of delays in enrollment, database lock or data readout; unfavorable or inconclusive clinical results; safety findings; regulatory delays or denials; financing requirements; competition; and the other risks described in the Company's filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date of this presentation, and the Company undertakes no obligation to update them except as required by law.

Any valuation metrics, comparable-company analyses, valuation ranges or potential valuation-inflection scenarios presented are illustrative and hypothetical. They are based on assumptions and circumstances that may not occur and do not constitute a projection, forecast, appraisal, estimate of fair or intrinsic value, price target, investment recommendation or guarantee of future stock price, market capitalization or financial performance. Comparable companies may differ materially from IGC Pharma, and there can be no assurance that favorable Phase 2 results, if obtained, would result in any increase in the Company's stock price or valuation.

Blinded pooled analyses combine participants assigned to IGC-AD1 and placebo and do not permit assessment of treatment effect or efficacy. Observed changes may reflect treatment effect, placebo response, regression to the mean, background care, trial participation, attrition or other factors. Such data are preliminary, may change following database cleaning and unblinding, and may not predict topline or final results. IGC-AD1 is investigational and has not been approved by the FDA or any other regulatory authority. Cross-trial comparisons are not head-to-head comparisons and are inherently limited.

OVERVIEW OF IGC

INVESTMENT OPPORTUNITY IN ALZHEIMER'S DISEASE (AD)

IGCPHARMA



Valuation scenarios are illustrative and hypothetical, not projections, forecasts, price targets, or guarantees.

IGCPHARMA

THE PROBLEM

One in three Americans over 85 has Alzheimer's

AGITATION IN ALZHEIMER'S

76%

of patients experience **agitation or other neuropsychiatric symptoms**

139M

people projected to live with **dementia by 2050** - **Alzheimer's is the leading cause**

Agitation is defined as physical or verbal aggression, restlessness, pacing, among others.

Agitation drives earlier institutionalization, higher mortality, and devastating caregiver burden.

Butler Hospital, Brown University • MedStar Franklin Square / Georgetown / Montgomery Medical Centers • University of South Florida Depart

OUR SOLUTION

IGC Pharma is Developing a Major Therapy

IGC-AD1 Therapeutic Targets

IGCPHARMA

Multiple neurobiological pathways targeted by IGC-AD1



Patent-protected

Oral liquid — practical for elderly Alzheimer's patients and caregivers

IGC-AD1

PHASE 1:

NPS MEASURED BY NPI-12

IGC-AD1 showed improvement in Neuropsychiatric Symptoms (NPS) in Phase 1 Trial

Across qd, bid, & tid dosing, IGC-AD1 led to an overall improvement in NPS as measured by the NPI-12

KEY DOMAINS SHOWING IMPROVEMENT:

- Agitation
- Anxiety
- Depression
- Caregiver Distress



Cohort 1
% Change
53.02%
p value: 0.005

Cohort 2
% Change
44.14%
p value: 0.024

Cohort 3
% Change
50.63%
p value: 0.021

PHASE 2 - CALMA TRIAL STATUS

The multicenter CALMA trial of IGC-AD1 for agitation in Alzheimer's dementia.

IGCPHARMA

Target number of participants **146**

>80% of participants have **completed dosing**

Previously reported interim analysis showed a reduction in agitation at 2 weeks

vs

6–10 weeks for the current standard of care, Brexpiprazole, based on published data.

NEAR-TERM CATALYSTS **Completion of enrollment + topline readout**

SITES CONDUCTING CALMA

UNITED STATES & CANADA

IGCPHARMA

Mount Sinai Hospital

BROWN

UNIVERSITY of SOUTH FLORIDA

MedStar Franklin Square Medical Center

Miami Jewish Health

Douglas FONDATION FOUNDATION

Hamilton Health Sciences

Baycrest

ADDITIONAL SITES

- Dent Neurosciences Research Center
- BayCare Health System
- ClinCloud
- Global Medical Institutes Florida
- Neurostudies
- Tandem Intermediate
- Tekton Research
- Integrative Clinical Trials
- Ichor Research
- Lynn Health Science Institute
- Senior Adults Specialty Research
- Dominion Medical Associates
- University of Puerto Rico
- SCB Research Center

CALMA PHASE 2 · PROGRESS REPORT

BLINDED POOLED DATA

IGCPHARMA

Blinded pooled data include both IGC-AD1 and placebo participants and cannot establish treatment effect or efficacy; observed changes may not predict unblinded results

WEEK 2
−13.6
LS mean change in CMAI from baseline (n=107)

WEEK 6
−14.9
LS mean change in CMAI from baseline

BLINDED POOLED

INVESTIGATIONAL

CALMA INTERIM RESULTS (N=26):

IGC-AD1 COMPARED TO BREXPIPRAZOLE DATA

- Brexpiprazole is the current standard of care to treat agitation in AD
- In interim analysis, IGC-AD1 showed numerically earlier and larger changes than those reported in selected published Brexpiprazole studies.

IGC AD-1: Potentially faster acting, larger effect size, and excellent safety profile



* CMAI Least Squared mean change from baseline at EOT comparing active and placebo groups A) IGC-AD1 1 ml BID trial (NCT05543681) and Brexpiprazole trial 0.5 to 2 mg flexible doses trial (NCT01922258). * p<0.05, ** p<0.01, b p<0.001; Mixed Model of Repeated Measures. SE: Standard Error; CMAI: Cohen-Mansfield Agitation Inventory.

• **This is a not a direct comparison** Grossberg GT, Kohegyi E, Mergel V, et al. Am J Geriatr Psychiatry. 2020;28(4):383-400. doi:10.1016/j.jagp.2019.09.009

INTERIM DATA (n=26) - POTENTIAL FOR REDUCING SLEEP DISTURBANCE

Clinical reduction in sleep & nighttime disturbance at week 2 sustained through End of Trial (EOT)

WEEK 2

Sleep Disturbance Reduced **71%**
(p=0.012)

WEEK 6 (EOT)

Sleep Disturbance Reduced **78%**
(p=0.02)

(1) NPI-12 Sleep Subdomain Least Squared Mean change from baseline comparing placebo and active groups in the interim data

APPROVED DRUGS (COMPETITION)

Rexulti (Brexpiprazole)

Atypical antipsychotic approved in May 2023

BLACK BOX WARNING

AXS-05 (Dextromethorphan and bupropion)

A combination therapy approved in April 2026.

IGC HAS SEVERAL PLATFORMS WITH IP

Lead Drug Candidate	Description	Pending Patent Applications	US Patents Granted	Foreign Patents Granted
IGC-AD1	• Composition & Method for treating CNS Disorders	1	2	-
IGC-AD1	• Composition & Method for treating CNS Disorders	9	1	1
TGR-63	• Naphthalene Monoimide Derivatives with ability to impact Aβ protein build-up.	6	-	-
IGC-1C	• Naphthalene Monoimide Derivatives with ability to impact Tau aggregation and neurofibrillary tangle formation	5	-	-
IGC-M3	• Naphthalene Monoimide Derivatives with ability to impact Aβ plaque build-up and neurofibrillary tangle formation	4	-	-
IGC-514	• Naphthalene diimide Derivatives with ability to self-assemble molecular interactions for biological and nonbiological systems including some cancers	0	1	1
IGC-LMP	• Composition, Synthesis & Medical use of Hybrid Molecule	1	-	-
Epilepsy	• Composition & Method for treating Seizures in humans & Cats/Dogs	-	2	-
Eating Disorders	• Natural formulation with Cyproheptadine for treating Cachexia & Eating Disorders	-	1	-
Stuttering & Tourette Syndrome	• Formulation for Treating Stuttering & Symptoms of Tourette Syndrome	-	1	-
Pain	• Formulation containing Cobalamin and method for pain management	-	2	2
IGC-AHA	• Multi agent system for end-to-end heterogenous data set harmonization	1	-	-
MINT-AD	• Explainable multimodal transformer-based system for neurodegenerative diseases clinical support	1	-	-
Sleep	• Methods and compositions for treating sleep disturbance and sleep–wake cycle disruption in alzheimer's disease	1	-	-
		29	10	4

We have 29 active patent applications which are distributed among the US, Canada, Europe, Colombia, India, Brazil, Japan and Hong Kong and 14 granted patents in US, Canada, Europe and Mexico.

● In-house patents / applications

● Patents / applications acquired through exclusive license agreements

POTENTIAL CATALYSTS

Laura Sanchez, Quality Control Manager & **Dr. Jagadeesh Rao,** Principal Scientist at IGC Pharma Headquarters in Potomac, Maryland

MARKET: BLOCKBUSTER OPPORTUNITY

North America & Europe market sizing for agitation in AD

EST. ANNUAL REVENUE



ASSUMPTIONS

15M*
Individuals with AD

11M
Agitation in AD (76%)

$750
Monthly price

** Sources: Alzheimer's Association, Alzheimer Europe, Harvard School of Public Health, Alzheimer's Disease International*

VALUATION INFLECTION EXAMPLES



COMPANY	PHASE 2		POST Positive PHASE 2 PEAK	DIFFERENCE
Annovis (ANVS) AD/PD	$200M (2021)	→	**$700M (2021)**	**~$500M**
Axsome (AXSM) AD	$50M (2019)	→	**$800M (2019)**	**~$750M**
Anavex AD/CNS	$150M (2016)	→	**$500M (2018)**	**~$350M**

Valuation scenarios are illustrative and positive phase 2 results, if obtained, may not result in any increase in IGC's stock price or market capitalization.

POTENTIAL VALUATION INFLECTION

Investors today are positioned before principal value-inflection events

Valuation scenarios are illustrative and positive phase 2 results, if obtained, may not result in any increase in IGC's stock price or market capitalization.

EXECUTIVE MANAGEMENT & BOARD

IGCPHARMA

EXECUTIVE MANAGEMENT

Ram Mukunda
Biomedical Engineer
CEO

Claudia Grimaldi
Psychologist, MBA,
Vice President

INDEPENDENT BOARD

Richard Prins
Chairman

James Moran
Former Congressman

Terry Lierman
Human Virology (IHV)

CORPORATE ADVISORY BOARD

Terry McAuliffe
Former Governor of Virginia

Howard Gutman
Ambassador to Belgium (rtd.)

CALMA TEAM

CLINICAL TRIAL: ALZ-AGITATION

IGCPHARMA

Dr. Juan Manuel Orjuela, MD
Neuropsychiatrist

Dr. Varduhi Ghazaryan,
MD-MPH - Medical Director

Evelyn Gutiérrez, Eng. MPH
Sr. Manager - CALMA

Margarita Venegas, MS
Clinical Psychologist

Dr. Jagadeesh Rao, Ph.D.
Doctorate in Neuroscience
Principal Scientist

Dr. Sudip Sinha, Ph.D.
Doctorate in Naturopathy
CALMA - Operations

Dr. Diego Rodriguez, Ph.D.
Medicinal Chemist

Maria Tangarife, MS
Neuroscientist

Paola Ruiz, MS
Sr. Manager
AI Systems

BOARD OF ADVISORS

IGCPHARMA

PHARMACEUTICAL SCIENCES, PSYCHIATRY, NEUROLOGY, STATISTICS, AND AI

Prof. Joseph Fortunak,
PhD
Professor Chemistry and Pharmaceutical Sciences

HOWARD UNIVERSITY

Prof. Chuanhai Cao,
PhD
Professor of Pharmaceutical Sciences

UNIVERSITY of SOUTH FLORIDA 1956

Prof. Elliot Hong,
MD
Professor Psychiatrist

TEXAS
The University of Texas at Austin

Prof. Jeffrey Cummings,
MD, ScD,
Chair of the ACTC Neuropsychiatric Symptoms Committee

ACTC
ALZHEIMER'S CLINICAL TRIALS CONSORTIUM

Dr. Munish Mehra,
PhD
Statistics

University of Kentucky

Prof. Pablo Arbelaez,
PhD
Professor Biomedical Engineering

DAUPHINE UNIVERSITÉ PARIS
Berkeley
UNIVERSITY OF CALIFORNIA

CONTACT

Ram Mukunda
ram@igcpharma.com

Claudia Grimaldi
cgrimaldi@igcpharma.com

www.igcpharma.com

IGCPHARMA

THANK YOU

Advancing **Alzheimer's Care**. Improving **Lives**.

NYSE American: IGC